8-K: NRC Health Announces Q2 2024 Results and Credit Agreement Amendment

NRC Health reported a slight decrease in revenue and earnings per share for the second quarter of 2024, while also announcing an amendment to their credit agreement and a new acquisition.

Summary

• National Research Corporation, also known as NRC Health, announced its second quarter 2024 financial results, with revenue of approximately $35 million, down from $36 million in the same quarter of 2023.
• Earnings per diluted share were $0.26, compared to $0.29 in the second quarter of 2023.
• The company's net indebtedness was approximately $42 million as of June 30, 2024.
• Total recurring contract value (TRCV) was approximately $138 million at the end of the quarter.
• NRC Health amended its credit agreement, extending the maturity of the revolving loan to May 28, 2027, and changing the interest rate on the term loan to SOFR plus 2.35%.
• The company also acquired NOBL Health for approximately $6 million in cash, plus a potential $1 million earnout, adding approximately $2 million in TRCV.
• A quarterly cash dividend of $0.12 per share was declared, payable on October 11, 2024, to shareholders of record on September 27, 2024.

Sentiment

Score: 6

Explanation: The sentiment is neutral to slightly positive. While there was a slight decrease in revenue and earnings, the credit agreement amendment, acquisition, and dividend announcement are positive developments. The lack of share repurchases in the quarter is a slight negative.

Positives

• The credit agreement amendment extends the maturity of the revolving loan to May 28, 2027, providing more financial flexibility.
• The acquisition of NOBL Health adds approximately $2 million in TRCV and expands the company's product offerings.
• The company declared a quarterly cash dividend of $0.12 per share, demonstrating a commitment to returning value to shareholders.
• The company has approximately 1.1 million shares remaining under its existing stock repurchase plan.

Negatives

• Revenue decreased slightly to approximately $35 million from $36 million in the same quarter last year.
• Earnings per diluted share decreased to $0.26 from $0.29 in the second quarter of 2023.
• The company did not repurchase any shares in the second quarter of 2024.

Risks

• The company's financial results are subject to risks and uncertainties, as detailed in their annual report and other filings.
• Forward-looking statements are based on current beliefs and expectations and are subject to change.
• The company's performance is subject to market conditions and competitive pressures.

Future Outlook

The company plans to release new consumer and employee experience capabilities, along with a new AI engine, and will continue to evaluate stock repurchases based on credit agreement limitations and future capital allocation decisions.

Management Comments

• Management is authorized to complete the stock repurchase plan in its discretion, credit agreement limitations, and future capital allocation decisions.
• The company has elected to include strategic updates normally discussed in earning calls to a broader group of current and potential stockholders via its quarterly earnings releases.

Industry Context

The healthcare technology industry is increasingly focused on patient and employee experience, and NRC Health's acquisition of NOBL Health and development of new CX and EX capabilities align with this trend. The company is also leveraging AI to enhance its offerings, which is a growing trend in the industry.

Comparison to Industry Standards

• While the document does not provide specific industry benchmarks, the slight decrease in revenue and earnings per share suggests that NRC Health may be facing similar challenges as other companies in the healthcare technology sector, such as increased competition or changing market dynamics.
• The acquisition of NOBL Health is a strategic move to enhance their product offerings, similar to other companies in the sector that are acquiring smaller players to expand their capabilities.
• The shift to a SOFR-based interest rate is a common practice in the current financial environment, reflecting a broader trend in the lending market.

Stakeholder Impact

• Shareholders will receive a quarterly cash dividend of $0.12 per share.
• Customers will benefit from new consumer and employee experience capabilities.
• Employees may see changes with the integration of NOBL Health and new technology.
• Creditors will be impacted by the amended credit agreement.

Next Steps

• The company will release new consumer experience (CX) capabilities.
• The company will release new employee experience (EX) capabilities.
• The company will release NOBL Health's rounding tool.
• The company will release a proprietary AI engine powering new products and features.
• The company will pay a quarterly cash dividend on October 11, 2024.
• The company will continue to evaluate stock repurchases.

Key Dates

Keywords

NRC Health, Financial Results, Credit Agreement, Acquisition, Dividend, Stock Repurchase, Healthcare Technology, Patient Experience, NOBL Health, SOFR